{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:33:48Z","timestamp":1791020028371,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,6,9]],"date-time":"2010-06-09T00:00:00Z","timestamp":1276041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,6,9]],"date-time":"2010-06-09T00:00:00Z","timestamp":1276041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s10637-010-9465-8","type":"journal-article","created":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T08:04:08Z","timestamp":1275984248000},"page":"1206-1212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells"],"prefix":"10.1007","volume":"29","author":[{"given":"Wei-Gang","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Estrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongtao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quin","family":"Van Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inbal","family":"Hazan-Halevy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,9]]},"reference":[{"key":"9465_CR1","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079\u20131082","journal-title":"Science"},{"key":"9465_CR2","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V91.11.3995","volume":"91","author":"S Faderl","year":"1998","unstructured":"Faderl S, Kantarjian HM, Talpaz M, Estrov Z (1998) Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 91:3995\u20134019","journal-title":"Blood"},{"key":"9465_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1053\/j.seminhematol.2006.01.007","volume":"43","author":"RA Larson","year":"2006","unstructured":"Larson RA (2006) Management of acute lymphoblastic leukemia in older patients. Semin Hematol 43:126\u2013133","journal-title":"Semin Hematol"},{"key":"9465_CR4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/asheducation-2007.1.435","volume":"2007","author":"DA Thomas","year":"2007","unstructured":"Thomas DA (2007) Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges. Hematology Am Soc Hematol Educ Program 2007:435\u2013443","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"9465_CR5","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1182\/blood.V86.12.4603.bloodjournal86124603","volume":"86","author":"JW Voncken","year":"1995","unstructured":"Voncken JW, Kaartinen V, Pattengale PK, Germeraad WT, Groffen J, Heisterkamp N (1995) BCR\/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood 86:4603\u20134611","journal-title":"Blood"},{"key":"9465_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3109\/10428190009148847","volume":"36","author":"S Faderl","year":"2000","unstructured":"Faderl S, Kantarjian HM, Thomas DA (2000) Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 36:263\u2013273","journal-title":"Leuk Lymphoma"},{"key":"9465_CR7","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","volume":"100","author":"H Dombret","year":"2002","unstructured":"Dombret H, Gabert J, Boiron JM (2002) Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood 100:2357\u20132366","journal-title":"Blood"},{"key":"9465_CR8","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038\u20131042","journal-title":"N Engl J Med"},{"key":"9465_CR9","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","volume":"103","author":"DA Thomas","year":"2004","unstructured":"Thomas DA, Faderl S, Cortes J, Kantarjian HM (2004) Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103:4396\u20134407","journal-title":"Blood"},{"key":"9465_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876\u2013880","journal-title":"Science"},{"key":"9465_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117\u2013125","journal-title":"Cancer Cell"},{"key":"9465_CR12","doi-asserted-by":"crossref","first-page":"14949","DOI":"10.1016\/S0021-9258(18)33376-3","volume":"257","author":"WJ Welch","year":"1982","unstructured":"Welch WJ, Feramisco JR (1982) Purification of the major mammalian heat shock proteins. J Biol Chem 257:14949\u201314959","journal-title":"J Biol Chem"},{"key":"9465_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1196\/annals.1391.012","volume":"1113","author":"P Workman","year":"2007","unstructured":"Workman P, Burrows F, Neckers L, Rosen N (2007) Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci 1113:202\u2013216","journal-title":"Ann NY Acad Sci"},{"key":"9465_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1078-0432.CCR-08-0132","volume":"15","author":"U Banerji","year":"2009","unstructured":"Banerji U (2009) Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15:9\u201314","journal-title":"Clin Cancer Res"},{"key":"9465_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1535-6108(03)00029-1","volume":"3","author":"JS Isaacs","year":"2003","unstructured":"Isaacs JS, Xu W, Neckers L (2003) Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3:213\u2013217","journal-title":"Cancer Cell"},{"key":"9465_CR16","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.juro.2007.05.120","volume":"178","author":"CR Williams","year":"2007","unstructured":"Williams CR, Tabios R, Linehan WM, Neckers L (2007) Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J Urol 178:1528\u20131532","journal-title":"J Urol"},{"key":"9465_CR17","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/(SICI)1097-4652(199603)166:3<618::AID-JCP17>3.0.CO;2-2","volume":"166","author":"Z Estrov","year":"1996","unstructured":"Estrov Z, Talpaz M, Zipf TF (1996) Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). J Cell Physiol 166:618\u2013630","journal-title":"J Cell Physiol"},{"key":"9465_CR18","first-page":"1534","volume":"10","author":"Z Estrov","year":"1996","unstructured":"Estrov Z, Talpaz M, Ku S (1996) Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF. Leukemia 10:1534\u20131543","journal-title":"Leukemia"},{"key":"9465_CR19","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1182\/blood.V94.8.2844.420k43_2844_2853","volume":"94","author":"Z Estrov","year":"1999","unstructured":"Estrov Z, Manna SK, Harris D (1999) Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood 94:2844\u20132853","journal-title":"Blood"},{"key":"9465_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0145-2126(02)00162-5","volume":"27","author":"S Faderl","year":"2003","unstructured":"Faderl S, Lotan R, Kantarjian HM, Harris D, Van Q, Estrov Z (2003) N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). Leuk Res 27:259\u2013266","journal-title":"Leuk Res"},{"key":"9465_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJM199701303360501","volume":"336","author":"WM Roberts","year":"1997","unstructured":"Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF (1997) Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 336:317\u2013323","journal-title":"N Engl J Med"},{"key":"9465_CR22","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.1365-2141.2007.06878.x","volume":"139","author":"AJ Johnson","year":"2007","unstructured":"Johnson AJ, Wagner AJ, Cheney CM (2007) Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol 139:837\u2013844","journal-title":"Br J Haematol"},{"key":"9465_CR23","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/sj.leu.2403764","volume":"19","author":"A Radujkovic","year":"2005","unstructured":"Radujkovic A, Schad M, Topaly J (2005) Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL-Inhibition of P-glycoprotein function by 17-AAG. Leukemia 19:1198\u20131206","journal-title":"Leukemia"},{"key":"9465_CR24","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/leu.2008.89","volume":"22","author":"LX Wu","year":"2008","unstructured":"Wu LX, Xu JH, Zhang KZ (2008) Disruption of the Bcr-Abl\/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin. Leukemia 22:1402\u20131409","journal-title":"Leukemia"},{"key":"9465_CR25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s12038-007-0051-y","volume":"32","author":"L Neckers","year":"2007","unstructured":"Neckers L (2007) Heat shock protein 90: the cancer chaperone. J Biosci 32:517\u2013530","journal-title":"J Biosci"},{"key":"9465_CR26","doi-asserted-by":"publisher","first-page":"8302","DOI":"10.1158\/1078-0432.CCR-08-1002","volume":"14","author":"DB Solit","year":"2008","unstructured":"Solit DB, Osman I, Polsky D (2008) Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 14:8302\u20138307","journal-title":"Clin Cancer Res"},{"key":"9465_CR27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3233\/BD-2002-15106","volume":"15","author":"L Neckers","year":"2002","unstructured":"Neckers L (2002) Heat shock protein 90 is a rational molecular target in breast cancer. Breast Dis 15:53\u201360","journal-title":"Breast Dis"},{"key":"9465_CR28","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood-2004-09-3413","volume":"105","author":"P George","year":"2005","unstructured":"George P, Bali P, Annvarapu S (2005) Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of the FLT-3. Blood 105:1768\u20131776","journal-title":"Blood"},{"key":"9465_CR29","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood-2004-09-3523","volume":"106","author":"RA Mesa","year":"2005","unstructured":"Mesa RA, Loegering D, Powell HL (2005) Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 106:318\u2013327","journal-title":"Blood"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9465-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-010-9465-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9465-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9465-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:01:57Z","timestamp":1678510917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-010-9465-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,9]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9465"],"URL":"https:\/\/doi.org\/10.1007\/s10637-010-9465-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,9]]},"assertion":[{"value":"16 April 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}